Looking Ahead in Oncology
We’ve been wondering – if CAR T-cell therapy, which is potentially curative in the liquid tumor space, proves effective in solid tumors as well, what does this mean for the targeted therapies and immuno-oncology agents which are currently dominating the treatment landscape in solid tumors?
- How will treaters trade-off the sky-high costs and logistical obstacles of CAR T-cell therapy with the familiarity, “simplicity” and relatively lower-priced treatments they are currently using for solid tumors?
- What could this mean for other emerging cell and gene therapies (i.e., TIL, TCR, NK) in the coming years?
- Dr. Jae Park
- Lisa Logan